{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:49:47Z","timestamp":1792450187473,"version":"4.5.0"},"reference-count":69,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post\u2010infusion CART expansion and persistence and for real\u2010time clinical decision\u2010making. Multiparameter flow cytometry (MFC) enables rapid, live\u2010cell detection with absolute quantification and concurrent immunophenotypic characterization. This review focuses on the practical and technical aspects of flow cytometry\u2013based CAR T\u2010cell monitoring, including selection of CAR detection reagents (target\u2010specific, construct\u2010specific, and target\u2010agnostic strategies), assay optimization, purpose\u2010driven panel design, and matrix\u2010appropriate validation for peripheral blood and other clinically relevant specimens. We also address assay considerations unique to gene\u2010edited allogeneic CAR T\u2010cell products, including the use of surrogate immunophenotypic approaches when construct\u2010specific reagents are unavailable. Finally, we discuss the role of MFC in identifying CAR T\u2010cell clonal expansions and in evaluating suspected secondary hematolymphoid neoplasms in the post\u2010CAR T setting.<\/jats:p>","DOI":"10.1002\/cyto.b.70026","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:06:21Z","timestamp":1774256781000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Flow cytometry\u2010based monitoring of chimeric antigen receptor (\n                    <scp>CAR<\/scp>\n                    ) T cells: Reagent selection, assay design, and clinical utility"],"prefix":"10.1002","author":[{"given":"Jianhua","family":"Ling","sequence":"first","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41590-023-01696-7","article-title":"CAR macrophages on a fast track to solid tumor therapy","volume":"25","author":"Abdin S. M.","year":"2024","journal-title":"Nature Immunology"},{"issue":"10254","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B\u2010cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson J. S.","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2023.1250508","article-title":"Elaborating the potential of artificial intelligence in automated CAR\u2010T cell manufacturing","volume":"3","author":"Backel N.","year":"2023","journal-title":"Frontiers in Molecular Medicine"},{"issue":"6","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T\u2010cell lymphomas after CAR T\u2010cell therapy","volume":"39","author":"Braun T.","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T\u2010cell therapies for lymphoma","volume":"15","author":"Brudno J. N.","year":"2018","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui T. A.","year":"2024","journal-title":"eBioMedicine"},{"issue":"3","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1148\/radiol.2018180449","article-title":"Clinical tracking of cell transfer and cell transplantation: Trials and tribulations","volume":"289","author":"Bulte J. W. M.","year":"2018","journal-title":"Radiology"},{"issue":"6","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long\u2010term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell K. M.","year":"2023","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cyto.a.24676","article-title":"Monitoring anti\u2010CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction","volume":"103","author":"Cheng J.","year":"2023","journal-title":"Cytometry. Part A"},{"issue":"11","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007515","article-title":"Chimeric antigen receptor T cells to target CD79b in B\u2010cell lymphomas","volume":"11","author":"Chu F. L.","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"6","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","article-title":"Idecabtagene vicleucel versus ciltacabtagene autoleucel: A Sophie's choice for patients with relapsed refractory multiple myeloma","volume":"15","author":"Davis J.","year":"2022","journal-title":"Expert Review of Hematology"},{"issue":"1","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: Progress made and remaining roadblocks","volume":"22","author":"Diorio C.","year":"2025","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"4","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T cell therapy in the DESCAR\u2010T registry","volume":"31","author":"Dulery R.","year":"2025","journal-title":"Nature Medicine"},{"issue":"20","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T\u2010cell therapy: Analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab M.","year":"2024","journal-title":"Blood"},{"issue":"2","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer L.","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell\u2010associated enterocolitis following chimeric antigen receptor T\u2010cell therapy in multiple myeloma","volume":"14","author":"Fortuna G. G.","year":"2024","journal-title":"Blood Cancer Journal"},{"issue":"5","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta J. A.","year":"2018","journal-title":"Nature Medicine"},{"issue":"11","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04134-9","article-title":"Development of antigen multimers for detection and evaluation of CAR T cells","volume":"74","author":"Friis R. U. W.","year":"2025","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22\u2010targeted CAR T cells induce remission in B\u2010ALL that is naive or resistant to CD19\u2010targeted CAR immunotherapy","volume":"24","author":"Fry T. J.","year":"2018","journal-title":"Nature Medicine"},{"issue":"4","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi G.","year":"2024","journal-title":"Nature Medicine"},{"issue":"9","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low\u2010affinity CD19 CAR","volume":"25","author":"Ghorashian S.","year":"2019","journal-title":"Nature Medicine"},{"key":"e_1_2_12_23_1","first-page":"e246","volume-title":"American Society of Clinical Oncology Educational Book","author":"Gill S.","year":"2021"},{"issue":"8","key":"e_1_2_12_24_1","article-title":"Evaluation of anti\u2010CAR linker mAbs for CAR T monitoring after BiTEs\/bsAbs and CAR T\u2010cell pretreatment","volume":"12","author":"Grahnert A.","year":"2024","journal-title":"Biomedicine"},{"issue":"22","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T\u2010cell lymphoma after CAR T\u2010cell therapy","volume":"390","author":"Hamilton M. P.","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.matt.2021.09.027","article-title":"Antigen\u2010Multimers: Specific, sensitive, precise, and multifunctional high\u2010avidity CAR\u2010staining reagents","volume":"4","author":"Hu Y.","year":"2021","journal-title":"Matter"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019115","article-title":"CAR\u2010T cell therapy for hematological malignancies: Limitations and optimization strategies","volume":"13","author":"Huang J.","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fcell.2024.1464218","article-title":"CAR\u2010macrophage: Breaking new ground in cellular immunotherapy","volume":"12","author":"Huang T.","year":"2024","journal-title":"Frontiers in Cell and Development Biology"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR\u2010T design: Elements and their synergistic function","volume":"58","author":"Jayaraman J.","year":"2020","journal-title":"eBioMedicine"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-1-0716-0203-4_19","article-title":"Monitoring allogeneic CAR\u2010T cells using flow cytometry","volume":"2097","author":"Jozwik A.","year":"2020","journal-title":"Methods in Molecular Biology"},{"issue":"6382","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June C. H.","year":"2018","journal-title":"Science"},{"issue":"1","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13139-014-0309-x","article-title":"In vivo cell tracking with bioluminescence imaging","volume":"49","author":"Kim J. E.","year":"2015","journal-title":"Nuclear Medicine and Molecular Imaging"},{"issue":"8","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T\u2010cell therapy for treatment of B\u2010cell lymphoma","volume":"3","author":"K\u00f6ksal H.","year":"2019","journal-title":"Blood Advances"},{"issue":"7949","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh L.","year":"2023","journal-title":"Nature"},{"issue":"3","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson R. C.","year":"2021","journal-title":"Nature Reviews. Cancer"},{"key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2023-179147","article-title":"Safety and efficacy of GPRC5D CAR T cell therapy in relapsed\/refractory multiple myeloma patients","volume":"142","author":"Li S. Q.","year":"2023","journal-title":"Blood"},{"issue":"8","key":"e_1_2_12_37_1","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li Y. R.","year":"2025","journal-title":"The Medicus"},{"issue":"6","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR\u2010transduced natural killer cells in CD19\u2010positive lymphoid tumors","volume":"382","author":"Liu E. L.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR\u2010T therapy in hematological malignancies","volume":"21","author":"Lu J.","year":"2022","journal-title":"Molecular Cancer"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"12695","DOI":"10.1182\/blood-2022-160106","article-title":"Developing CD70\u2010targeted CAR\u2010T cells for the treatment of hematological and solid malignancies","volume":"140","author":"Lu Y.","year":"2022","journal-title":"Blood"},{"issue":"7","key":"e_1_2_12_41_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101628","article-title":"Chimeric antigen receptor\u2010induced antigen loss protects CD5.CART cells from fratricide without compromising on\u2010target cytotoxicity","volume":"5","author":"Ma R. Y.","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR\u2010T cells in hematological malignancies","volume":"24","author":"Mansoori S.","year":"2024","journal-title":"Cancer Cell International"},{"issue":"6","key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti\u2010B\u2010cell maturation antigen chimeric antigen receptor T\u2010cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE\u20101 2\u2010year follow\u2010up","volume":"41","author":"Martin T.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and Young adults with B\u2010cell lymphoblastic leukemia","volume":"378","author":"Maude S. L.","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan A. D.","year":"2019","journal-title":"Immunology and Cell Biology"},{"issue":"1","key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR\u2010T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei H.","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"key":"e_1_2_12_47_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: The history and progress of CAR T cell therapy","volume":"14","author":"Mitra A.","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi N. C.","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T\u2010cell therapy in refractory large B\u2010cell lymphoma","volume":"377","author":"Neelapu S. S.","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"e_1_2_12_50_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of circulating CAR T cells: Validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following Tisagenlecleucel","volume":"13","author":"Peinelt A.","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey A. D.","year":"2024","journal-title":"Trends Cancer"},{"issue":"2","key":"e_1_2_12_52_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020903","article-title":"Comparison of FACS and PCR for detection of BCMA\u2010CAR\u2010T cells","volume":"23","author":"Reichman A.","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"23","key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in adults with B\u2010cell acute lymphoblastic leukemia","volume":"391","author":"Roddie C.","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"e_1_2_12_54_1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177160","article-title":"CAR T cells for hematological malignancies","volume":"134","author":"Savoldo B.","year":"2024","journal-title":"The Journal of Clinical Investigation"},{"issue":"11","key":"e_1_2_12_55_1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113208","article-title":"Sensitivity and specificity of CD19.CAR\u2010T cell detection by flow cytometry and PCR","volume":"10","author":"Schanda N.","year":"2021","journal-title":"Cells"},{"issue":"3","key":"e_1_2_12_56_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101328","article-title":"Linker\u2010specific monoclonal antibodies present a simple and reliable detection method for scFv\u2010based CAR NK cells","volume":"32","author":"Schindler K.","year":"2024","journal-title":"Molecular Therapy \u2013 Methods and Clinical Development"},{"key":"e_1_2_12_57_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557157","article-title":"Allogeneic CART progress: Platforms, current progress and limitations","volume":"16","author":"Shokati A.","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_58_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2025.113970","article-title":"CAR binding efficacy and off\u2010target interactions for common CAR detection reagents","volume":"544","author":"Sinapius R.","year":"2025","journal-title":"Journal of Immunological Methods"},{"issue":"24","key":"e_1_2_12_59_1","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun C.","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"e_1_2_12_60_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman A. D.","year":"2020","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"e_1_2_12_61_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-024-01105-8","article-title":"Bispecific CAR\u2010T cells targeting CD19\/20 in patients with relapsed or refractory B cell non\u2010Hodgkin lymphoma: A phase I\/II trial","volume":"14","author":"Wang L.","year":"2024","journal-title":"Blood Cancer Journal"},{"issue":"14","key":"e_1_2_12_62_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE\u2010X19 CAR T\u2010cell therapy in relapsed or refractory mantle\u2010cell lymphoma","volume":"382","author":"Wang M.","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"e_1_2_12_63_1","article-title":"Preclinical evaluation of CD70\u2010specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu G. Q.","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"e_1_2_12_64_1","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","article-title":"An \u201coff\u2010the\u2010shelf\u201d CD2 universal CAR\u2010T therapy for T\u2010cell malignancies","volume":"37","author":"Xiang J. Y.","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_65_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncponc1278","article-title":"Noninvasive detection of therapeutic cytolytic T cells with F\u2010FHBG PET in a patient with glioma","volume":"6","author":"Yaghoubi S. S.","year":"2009","journal-title":"Nature Clinical Practice. Oncology"},{"key":"e_1_2_12_66_1","first-page":"13","article-title":"A bibliometric and scientific knowledge\u2010map study of the chimeric antigen receptor (CAR) natural killer (NK) cell\u2010related research from 2010 to 2022","volume":"13","author":"Zhang J.","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_67_1","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20\u2010directed chimeric antigen receptor\u2010modified T cells in patients with relapsed or refractory B\u2010cell non\u2010Hodgkin lymphoma: An early phase IIa trial report","volume":"1","author":"Zhang W. Y.","year":"2016","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"e_1_2_12_68_1","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1182\/blood-2022-165733","article-title":"A novel universal CD7\u2010targeted CAR\u2010T cell therapy for relapsed or refractory T\u2010cell acute lymphoblastic leukemia and T\u2010cell lymphoblastic lymphoma","volume":"140","author":"Zhang X.","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_69_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti\u2010CD7 CAR\u2010T cell therapies in relapsed or refractory T\u2010cell malignancies","volume":"13","author":"Zhang Y.","year":"2023","journal-title":"Blood Cancer Journal"},{"key":"e_1_2_12_70_1","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-29","article-title":"Protein L: A novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry","volume":"10","author":"Zheng Z.","year":"2012","journal-title":"Journal of Translational Medicine"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.70026","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cyto.b.70026","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.70026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:06:30Z","timestamp":1774256790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.70026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":69,"alternative-id":["10.1002\/cyto.b.70026"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.70026","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"2026-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cyto.b.70026"}}